Page 1510 - Hematology_ Basic Principles and Practice ( PDFDrive )

1342 Part VII Hematologic Malignancies

Castellino SM, Geiger AM, Mertens AC, et al: Morbidity and mortality in the German BFM (Berlin-Frankfurt-Münster) Multicenter Trial. Blood
long-term survivors of Hodgkin lymphoma: a report from the Childhood 107:4047, 2006.
Cancer Survivor Study. Blood 117:1806, 2011. Patte C, Auperin A, Gerrard M, et al: Results of the randomized international
Ducassou S, Ferlay C, Bergeron C, et al: Clinical presentation, evolution, and FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in
prognosis of precursor B-cell lymphoblastic lymphoma in trials LMT96, children and adolescents: it is possible to reduce treatment for the early
EORTC 58881, and EORTC 58951. Br J Haematol 152:441, 2011. responding patients. Blood 109:2773, 2007.
Dunleavy K, Pittaluga S, Maeda LS, et al: Dose-adjusted EPOCH-rituximab Poirel HA, Cairo MS, Heerema NA, et al: Specific cytogenetic abnormali-
therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368:1408, ties are associated with a significantly inferior outcome in children and
2013. adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the
Friedman DL, Chen L, Wolden S, et al: Dose-intensive response-based FAB/LMB 96 international study. Leukemia 23:323, 2009.
chemotherapy and radiation therapy for children and adolescents with Pro B, Advani R, Brice P, et al: Brentuximab vedotin (SGN-35) in patients
newly diagnosed intermediate-risk Hodgkin lymphoma: a report from the with relapsed or refractory systemic anaplastic large-cell lymphoma:
Children’s Oncology Group Study AHOD0031. J Clin Oncol 32:3651, results of a phase II study. J Clin Oncol 30:2190, 2012.
2014. Salzburg J, Burkhardt B, Zimmermann M, et al: Prevalence, clinical pattern,
Gambacorti-Passerini C, Messa C, Pogliani EM: Crizotinib in anaplastic and outcome of CNS involvement in childhood and adolescent non-
large-cell lymphoma. N Engl J Med 364:775, 2011. Hodgkin’s lymphoma differ by non-Hodgkin’s lymphoma subtype: a
Goldman S, Smith L, Anderson JR, et al: Rituximab and FAB/LMB 96 che- Berlin-Frankfurt-Münster Group Report. J Clin Oncol 25:3915, 2007.
motherapy in children with stage III/IV B-cell non-Hodgkin lymphoma: Sandlund JT, Downing JR, Crist WM: Non-Hodgkin’s lymphoma in child-
a Children’s Oncology Group report. Leukemia 27:1174, 2013. hood. N Engl J Med 334:1238, 1996.
Gross TG, Orjuela MA, Perkins SL, et al: Low-dose chemotherapy and ritux- Schmitz R, Young RM, Ceribelli M, et al: Burkitt lymphoma pathogenesis
imab for posttransplant lymphoproliferative disease (PTLD): a Children’s and therapeutic targets from structural and functional genomics. Nature
Oncology Group report. Am J Transplant 12:3069, 2012. 490:116, 2012.
Lamant L, McCarthy K, d’Amore E, et al: Prognostic impact of morphologic Schwartz CL, Constine LS, Villaluna D, et al: A risk-adapted, response-based
and phenotypic features of childhood ALK-positive anaplastic large-cell approach using ABVE-PC for children and adolescents with intermediate-
lymphoma: results of the ALCL99 study. J Clin Oncol 29:4669, 2011. and high-risk Hodgkin lymphoma: the results of P9425. Blood 114:2051,
Le Deley MC, Rosolen A, Williams DM, et al: Vinblastine in children and 2009.
adolescents with high-risk anaplastic large-cell lymphoma: results of the Woessmann W, Seidemann K, Mann G, et al: The impact of the methotrex-
randomized ALCL99-vinblastine trial. J Clin Oncol 28:3987, 2010. ate administration schedule and dose in the treatment of children and
Mauz-Körholz C, Hasenclever D, Dorffel W, et al: Procarbazine-free OEPA- adolescents with B-cell neoplasms: a report of the BFM Group Study
COPDAC chemotherapy in boys and standard OPPA-COPP in girls NHL-BFM95. Blood 105:948, 2005.
have comparable effectiveness in pediatric Hodgkin’s lymphoma: the Wolden SL, Chen L, Kelly KM, et al: Long-term results of CCG 5942: a
GPOH-HD-2002 study. J Clin Oncol 28:3680, 2010. randomized comparison of chemotherapy with and without radiotherapy
Meinhardt A, Burkhardt B, Zimmermann M, et al: Phase II window study for children with Hodgkin’s lymphoma—a report from the Children’s
on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin’s Oncology Group. J Clin Oncol 30:3174, 2012.
lymphoma and Burkitt leukemia. J Clin Oncol 28:3115, 2010. Younes A, Bartlett NL, Leonard JP, et al: Brentuximab vedotin (SGN-35)
Minard-Colin V, Brugières L, Reiter A, et al: Non-Hodgkin lymphoma in for relapsed CD30-positive lymphomas. N Engl J Med 363:1812, 2010.
children and adolescents: progress through effective collaboration, current
knowledge, and challenges ahead. J Clin Oncol 33:2963, 2015.
Oschlies I, Klapper W, Zimmermann M, et al: Diffuse large B-cell lymphoma REFERENCES
in pediatric patients belongs predominantly to the germinal-center type
B-cell lymphomas: a clinicopathologic analysis of cases included in For the complete list of references, log on to www.expertconsult.com.